OBJECTIVE: To establish pregnancy-specific free thyroxine thresholds and to assess perinatal effects associated with isolated maternal hypothyroxinemia identified in the first half of pregnancy. METHODS: Stored serum samples from 17,298 women who previously underwent thyroid-stimulating hormone (TSH) screening in the first half of pregnancy were analyzed for free thyroxine (T(4)) concentrations and thyroid peroxidase antibodies. Women with a free T(4) below 0.86 ng/dL but a normal-range TSH were identified to have isolated maternal hypothyroxinemia. Pregnancy outcomes in these women were compared to those with a normal TSH and free T(4). Thyroid peroxidase antibody status and the relationship between TSH and free T(4) were analyzed for these women and women with subclinical hypothyroidism. RESULTS: Isolated maternal hypothyroxinemia was identified in 233 women (1.3%). There were not any excessive adverse pregnancy outcomes in these women. Positive thyroid peroxidase antibody assays (greater than 50 international units/mL) were similar in normal women (4%) and those with isolated hypothyroxinemia (5%) but were greater in women with subclinical hypothyroidism (31%, P<.001). There was a negative correlation between TSH and free T(4) in normal women (r(s)=-0.19, P<.001) and those with subclinical hypothyroidism (r(s)=-0.11, P=.007). The correlation in women with isolated hypothyroxinemia was not significant. CONCLUSION: Isolated maternal hypothyroxinemia has no adverse effects on perinatal outcome. Moreover, unlike subclinical hypothyroidism, there was a low prevalence of thyroid peroxidase antibodies and no correlation between TSH and free T(4) levels in women with hypothyroxinemia, leading us to question its biological significance.
OBJECTIVE: To establish pregnancy-specific free thyroxine thresholds and to assess perinatal effects associated with isolated maternal hypothyroxinemia identified in the first half of pregnancy. METHODS: Stored serum samples from 17,298 women who previously underwent thyroid-stimulating hormone (TSH) screening in the first half of pregnancy were analyzed for free thyroxine (T(4)) concentrations and thyroid peroxidase antibodies. Women with a free T(4) below 0.86 ng/dL but a normal-range TSH were identified to have isolated maternal hypothyroxinemia. Pregnancy outcomes in these women were compared to those with a normal TSH and free T(4). Thyroid peroxidase antibody status and the relationship between TSH and free T(4) were analyzed for these women and women with subclinical hypothyroidism. RESULTS: Isolated maternal hypothyroxinemia was identified in 233 women (1.3%). There were not any excessive adverse pregnancy outcomes in these women. Positive thyroid peroxidase antibody assays (greater than 50 international units/mL) were similar in normal women (4%) and those with isolated hypothyroxinemia (5%) but were greater in women with subclinical hypothyroidism (31%, P<.001). There was a negative correlation between TSH and free T(4) in normal women (r(s)=-0.19, P<.001) and those with subclinical hypothyroidism (r(s)=-0.11, P=.007). The correlation in women with isolated hypothyroxinemia was not significant. CONCLUSION: Isolated maternal hypothyroxinemia has no adverse effects on perinatal outcome. Moreover, unlike subclinical hypothyroidism, there was a low prevalence of thyroid peroxidase antibodies and no correlation between TSH and free T(4) levels in women with hypothyroxinemia, leading us to question its biological significance.
Authors: Shristi Rawal; Michael Y Tsai; Stefanie N Hinkle; Yeyi Zhu; Wei Bao; Yuan Lin; Pranati Panuganti; Paul S Albert; Ronald C W Ma; Cuilin Zhang Journal: J Clin Endocrinol Metab Date: 2018-07-01 Impact factor: 5.958
Authors: Lauren E Johns; Kelly K Ferguson; David E Cantonwine; Bhramar Mukherjee; John D Meeker; Thomas F McElrath Journal: J Clin Endocrinol Metab Date: 2018-04-01 Impact factor: 5.958
Authors: M Altomare; S La Vignera; P Asero; D Recupero; R A Condorelli; P Scollo; A Gulisano; E Magro; D Tumino; S Tumino; E Vicari; V Leanza; R D'Agata; A E Calogero Journal: J Endocrinol Invest Date: 2012-10-22 Impact factor: 4.256
Authors: Geralyn Lambert-Messerlian; Monica McClain; James E Haddow; Glenn E Palomaki; Jacob A Canick; Jane Cleary-Goldman; Fergal D Malone; T Flint Porter; David A Nyberg; Peter Bernstein; Mary E D'Alton Journal: Am J Obstet Gynecol Date: 2008-07 Impact factor: 8.661